A M Gray|P R Flatt - JoVE Visualize

Showing results (251-260 of 289) with videos related to

Pageof 29

Sort By:

Epidemiology and Infection|November 18, 1997

An economic analysis of varicella vaccination for health care workersA M Gray, P Fenn, J Weinberg, et al.

The Journal of Endocrinology|April 3, 2002

Evidence for a sustained increase in clonal beta-cell basal intracellular Ca2+ levels after incubation in the presence of newly diagnosed Type-1 diabetic patient sera. Possible role in serum-induced inhibition of insulin secretionS J Conroy, I Green, G Dixon, et al.

Molecular and Cellular Endocrinology|November 27, 2015

Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic miceP J B Millar, V Pathak, R C Moffett, et al.

Diabetes, Obesity & Metabolism|May 2, 2015

Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharideS Patterson, M de Kort, N Irwin, et al.

Journal of Molecular Endocrinology|December 11, 2003

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivoB D Green, V A Gault, M H Mooney, et al.

Metabolism: Clinical and Experimental|February 10, 2004

Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)B D Green, M H Mooney, V A Gault, et al.

Journal of Neurochemistry|August 26, 1999

The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatumA M Gray, S M Rawls, T S Shippenberg, et al.

Brain Research. Molecular Brain Research|October 26, 1999

Autoradiographic evidence that intrastriatal administration of adenosine A(1) receptor antisense oligodeoxynucleotide decreases adenosine A(1) receptors in the rat striatum and cortexT A Phan, A M Gray, J W Nyce, et al.

The Journal of Endocrinology|March 12, 2004

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activityB D Green, M H Mooney, V A Gault, et al.

The Journal of Endocrinology|October 27, 2006

Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob miceJ C Parker, K S Lavery, N Irwin, et al.

Pageof 29

Showing results (251-260 of 289) with videos related to

Sort By:

Pageof 29

Epidemiology and Infection|November 18, 1997

An economic analysis of varicella vaccination for health care workersA M Gray, P Fenn, J Weinberg, et al.

The Journal of Endocrinology|April 3, 2002

Evidence for a sustained increase in clonal beta-cell basal intracellular Ca2+ levels after incubation in the presence of newly diagnosed Type-1 diabetic patient sera. Possible role in serum-induced inhibition of insulin secretionS J Conroy, I Green, G Dixon, et al.

Molecular and Cellular Endocrinology|November 27, 2015

Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic miceP J B Millar, V Pathak, R C Moffett, et al.

Diabetes, Obesity & Metabolism|May 2, 2015

Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharideS Patterson, M de Kort, N Irwin, et al.

Journal of Molecular Endocrinology|December 11, 2003

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivoB D Green, V A Gault, M H Mooney, et al.

Metabolism: Clinical and Experimental|February 10, 2004

Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)B D Green, M H Mooney, V A Gault, et al.

Journal of Neurochemistry|August 26, 1999

The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatumA M Gray, S M Rawls, T S Shippenberg, et al.

Brain Research. Molecular Brain Research|October 26, 1999

Autoradiographic evidence that intrastriatal administration of adenosine A(1) receptor antisense oligodeoxynucleotide decreases adenosine A(1) receptors in the rat striatum and cortexT A Phan, A M Gray, J W Nyce, et al.

The Journal of Endocrinology|March 12, 2004

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activityB D Green, M H Mooney, V A Gault, et al.

The Journal of Endocrinology|October 27, 2006

Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob miceJ C Parker, K S Lavery, N Irwin, et al.

Pageof 29